

Clinical Trial Supplies - Company Evaluation Report, 2025

Market Report | 2025-08-01 | 108 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$2650.00
- Corporate License \$4250.00

Report description:

The Clinical Trial Supplies Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Clinical Trial Supplies. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 120 companies, of which the Top 17 Clinical Trial Supplies Companies were categorized and recognized as the quadrant leaders.

The clinical trial supplies market is experiencing significant growth, driven by the increasing complexity of clinical trials, the rise in biologics and personalized medicine, and the globalization of clinical research. To manage costs, ensure regulatory compliance, and improve logistical efficiency, pharmaceutical and biotechnology companies are increasingly outsourcing supply chain operations to specialized service providers. Key innovations such as temperature-controlled packaging, direct-to-patient (DTP) delivery models, and the rise of decentralized clinical trials are accelerating demand for advanced supply chain solutions. The growing adoption of biologics, as well as cell and gene therapies, has further increased the need for robust cold chain logistics, real-time temperature monitoring, and cryogenic storage capabilities.

Digital transformation is also reshaping clinical trial supply management. AI-powered demand forecasting, blockchain-enabled transparency, and cloud-based inventory systems are enhancing operational efficiency and data integrity. As a result, pharmaceutical and biotech firms are partnering more frequently with Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) to access integrated, end-to-end clinical trial supply solutions-further fueling market expansion.

The 360 Quadrant maps the Clinical Trial Supplies companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Clinical Trial Supplies quadrant. The top criteria for product footprint evaluation included Service (logistics & distribution, storage & retention, packaging, labeling and blinding, manufacturing, comparator sourcing and other services) phase (Phase III, Phase II, Phase I, Phase IV, and Phase BA/BE) type (small molecules, biologics, and medical devices) therapeutic area (oncology, neurology, respiratory disorders, metabolic disorders/endocrinology, cardiovascular system disorders, dermatology, gastrointestinal system disorders, immunological disorders, infectious diseases, psychiatry, ophthalmology, hematology, genitourinary & women's health, and other therapeutic areas).

Key Players:

Some of the prominent players are Thermo Fisher Scientific Inc. (US), Novo Holdings A/S (Denmark), Marken (UPS) (US), Eurofins

Scientific (Luxembourg), Piramal Group (India), Almac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), and Sharp Services LLC (US), and others. These players are increasingly focusing on product launches and enhancements, investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, sales contracts, and alliances to strengthen their presence in the global market.

Top 3 Companies

Thermo Fisher Scientific

Thermo Fisher Scientific is a global leader in science and technology, specializing in high-end analytical instruments, laboratory equipment, consumables, reagents, software, and services that support scientific research, discovery, diagnostics, and analysis. The company operates through four primary business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services. Thermo Fisher's presence in the clinical trial supplies market is anchored through its subsidiary PPD, which falls under the Laboratory Products & Biopharma Services segment. The company delivers a wide range of solutions through its prominent brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.

Sharp Services LLC

Sharp Services is a global provider of contract packaging and clinical trial supply solutions, serving the pharmaceutical, biotechnology, and life sciences industries. The company delivers end-to-end clinical trial services including GMP-compliant primary and secondary packaging, multi-language labeling, blinding services, cold chain logistics, Just-in-Time (JIT) labeling, and global storage and distribution. Sharp supports both clinical and commercial needs while ensuring regulatory compliance and operational flexibility. Headquartered in the United States, Sharp maintains GMP-certified facilities in the U.S. and the U.K., with operations extending across North America and Europe. Its key subsidiaries include Sharp Laboratories of America, Inc. (SLA), Sharp Hong Kong Limited (SHK), Sharp Manufacturing (Thailand) Co., Ltd. (SMTL), and Sharp Corporation of Australia Pty. Ltd. (SCA).

Parexel International

Parexel International is a leading contract research organization (CRO) that offers comprehensive drug development and regulatory services to pharmaceutical, biotech, and medical device companies. Its core business segment, Clinical Research Services (CRS), encompasses full-spectrum clinical trial management from Phase I to Phase IV, along with biostatistics, pharmacovigilance, data management, regulatory affairs, market access consulting, observational studies, and clinical logistics. Headquartered in the U.S., Parexel has a strong international footprint, with 85 offices across 52 countries. Notable subsidiaries include Parexel International S.A. (Argentina), Parexel Belgium SPRL, Parexel International, LLC (U.S.), Parexel International (Canada) Ltd., Parexel China Ding Hui Co., Ltd., Parexel International GmbH (Germany), Parexel International Limited (UK), and Parexel International Inc. (Japan).

Table of Contents:

1 INTRODUCTION	11
1.1 MARKET DEFINITION	11
1.2 INCLUSIONS & EXCLUSIONS	11
1.3 STAKEHOLDERS	11
2 EXECUTIVE SUMMARY	12
3 MARKET OVERVIEW	17
3.1 INTRODUCTION	17
3.2 MARKET DYNAMICS	18
3.2.1 DRIVERS	18
3.2.1.1 Growth in clinical trials & drug development	18
3.2.1.2 Expansion of global and multicenter trials accelerating demand for clinical trial supplies	19
3.2.1.3 Rising demand for personalized medicine and biologics	20
3.2.2 RESTRAINTS	20
3.2.2.1 High costs associated with clinical trial supplies	20

3.2.3 OPPORTUNITIES	21
3.2.3.1 Rise in decentralized and virtual trials	21
3.2.3.2 Integration of digital technologies in supply chain management	21
3.2.4 CHALLENGES	21
3.2.4.1 Supply chain disruptions and drug shortages	21
3.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	22
3.4 VALUE CHAIN ANALYSIS	23
3.5 ECOSYSTEM ANALYSIS	25
3.5.1 CLINICAL TRIAL SUPPLIES MARKET: RAW MATERIAL PROVIDERS	26
3.5.2 CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS	26
3.5.3 CLINICAL TRIAL SUPPLIES MARKET: END USERS	27
3.5.4 CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES	27
3.6 TECHNOLOGY ANALYSIS	28
3.6.1 KEY TECHNOLOGIES	28
3.6.1.1 Serialization & track-and-trace technologies	28
3.6.1.2 Interactive response technology (IRT/IVR/IWR)	28
3.6.1.3 Cold chain & temperature monitoring solutions	28
3.6.2 COMPLEMENTARY TECHNOLOGIES	28
3.6.2.1 Artificial intelligence (AI) & machine learning (ML)	28
3.6.2.2 Blockchain for supply chain transparency	29
?	
3.6.3 ADJACENT TECHNOLOGIES	29
3.6.3.1 Cryopreservation & advanced storage technologies	29
3.6.3.2 Advanced robotics in warehousing & distribution	29
3.7 KEY CONFERENCES AND EVENTS, 2025-2026	29
3.8 PORTER'S FIVE FORCES ANALYSIS	30
3.8.1 THREAT OF NEW ENTRANTS	31
3.8.2 BARGAINING POWER OF SUPPLIERS	31
3.8.3 BARGAINING POWER OF BUYERS	32
3.8.4 THREAT OF SUBSTITUTES	32
3.8.5 INTENSITY OF COMPETITIVE RIVALRY	32
3.9 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL SUPPLIES MARKET	32
3.9.1 INTRODUCTION	32
3.9.2 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL SUPPLIES ECOSYSTEM	34
4 COMPETITIVE LANDSCAPE	35
4.1 INTRODUCTION	35
4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN	35
4.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET	35
4.3 REVENUE ANALYSIS, 2020-2024	36
4.4 MARKET SHARE ANALYSIS, 2024	37
4.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	40
4.5.1 STARS	40
4.5.2 EMERGING LEADERS	40
4.5.3 PERVERSIVE PLAYERS	40
4.5.4 PARTICIPANTS	40
4.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024	42
4.5.5.1 Company footprint	42

4.5.5.2 Region footprint	42
4.5.5.3 Service footprint	43
4.5.5.4 Type footprint	44
4.5.5.5 End-user footprint	45
4.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	45
4.6.1 PROGRESSIVE COMPANIES	45
4.6.2 RESPONSIVE COMPANIES	45
4.6.3 DYNAMIC COMPANIES	46
4.6.4 STARTING BLOCKS	46
4.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	47
4.6.5.1 Detailed list of key startups/SMEs	47
4.6.5.2 Competitive benchmarking of key startups/SMEs	48
?	
4.7 COMPANY VALUATION & FINANCIAL METRICS	49
4.7.1 COMPANY VALUATION	49
4.7.2 FINANCIAL METRICS	49
4.8 BRAND/SERVICE COMPARISON	50
4.9 COMPETITIVE SCENARIO	51
4.9.1 DEALS	51
4.9.2 EXPANSIONS	51
5 COMPANY PROFILES	53
5.1 KEY PLAYERS	53
5.1.1 THERMO FISHER SCIENTIFIC INC.	53
5.1.1.1 Business overview	53
5.1.1.2 Services offered	54
5.1.1.3 Recent developments	55
5.1.1.3.1 Service launches	55
5.1.1.3.2 Deals	55
5.1.1.3.3 Expansions	56
5.1.1.4 MnM view	56
5.1.1.4.1 Right to win	56
5.1.1.4.2 Strategic choices	56
5.1.1.4.3 Weaknesses & competitive threats	56
5.1.2 NOVO HOLDINGS A/S	57
5.1.2.1 Business overview	57
5.1.2.2 Services offered	58
5.1.2.3 Recent developments	59
5.1.2.3.1 Deals	59
5.1.2.3.2 Expansions	60
5.1.2.4 MnM view	60
5.1.2.4.1 Right to win	60
5.1.2.4.2 Strategic choices	60
5.1.2.4.3 Weaknesses & competitive threats	60
5.1.3 UNITED PARCEL SERVICE OF AMERICA, INC.	61
5.1.3.1 Business overview	61
5.1.3.2 Services offered	61
5.1.3.3 MnM view	62

5.1.3.3.1 Right to win	62
5.1.3.3.2 Strategic choices	62
5.1.3.3.3 Weaknesses & competitive threats	63
5.1.4 EUROFINS SCIENTIFIC	64
5.1.4.1 Business overview	64
5.1.4.2 Services offered	65
5.1.4.3 MnM view	66
5.1.4.3.1 Right to win	66
5.1.4.3.2 Strategic choices	66
5.1.4.3.3 Weaknesses & competitive threats	66
5.1.5 PIRAMAL PHARMA LIMITED	67
5.1.5.1 Business overview	67
5.1.5.2 Services offered	68
5.1.5.3 MnM view	69
5.1.5.3.1 Right to win	69
5.1.5.3.2 Strategic choices	69
5.1.5.3.3 Weaknesses & competitive threats	69
5.1.6 IQVIA	70
5.1.6.1 Business overview	70
5.1.6.2 Services offered	72
5.1.7 ICON PLC	73
5.1.7.1 Business overview	73
5.1.7.2 Services offered	74
5.1.7.3 Recent developments	75
5.1.7.3.1 Deals	75
5.1.8 LONZA	76
5.1.8.1 Business overview	76
5.1.8.2 Services offered	77
5.1.8.3 Recent developments	77
5.1.8.3.1 Deals	77
5.1.9 UNIPHAR GROUP PLC	78
5.1.9.1 Business overview	78
5.1.9.2 Services offered	79
5.1.10 ALMAC GROUP	80
5.1.10.1 Business overview	80
5.1.10.2 Services offered	80
5.1.10.3 Recent developments	81
5.1.10.3.1 Expansions	81
5.1.11 SHARP SERVICES, LLC	82
5.1.11.1 Business overview	82
5.1.11.2 Services offered	82
5.1.12 PCI PHARMA SERVICES	84
5.1.12.1 Business overview	84
5.1.12.2 Services offered	84
5.1.12.3 Recent developments	85
5.1.12.3.1 Expansions	85
?	

5.1.13 PAREXEL INTERNATIONAL (MA) CORPORATION 86

5.1.13.1 Business overview 86

5.1.13.2 Services offered 86

5.1.13.3 Recent developments 87

5.1.13.3.1 Deals 87

5.1.14 BIOCAIR 88

5.1.14.1 Business overview 88

5.1.14.2 Services offered 88

5.2 OTHER PLAYERS 89

5.2.1 CENCORA, INC. 89

5.2.2 CLINIGEN LIMITED 90

5.2.3 KLIFO 91

5.2.4 IPS PHARMA 92

5.2.5 COREX LOGISTICS LIMITED 93

5.2.6 OCT GROUP LLC 94

5.2.7 MYONEX 95

5.2.8 INCEPTUA GROUP 96

5.2.9 ANCILLARE, LP 97

5.2.10 ADALLEN PHARMA 98

5.2.11 CLINICAL SERVICES INTERNATIONAL (CSI) 99

5.2.12 NUVISAN GMBH 100

5.2.13 AENOVA HOLDING GMBH 101

6 APPENDIX 102

6.1 RESEARCH METHODOLOGY 102

6.1.1 RESEARCH DATA 102

6.1.1.1 Secondary data 102

6.1.1.2 Primary research 103

6.1.2 RESEARCH ASSUMPTIONS 103

6.1.3 RESEARCH LIMITATIONS 104

6.1.4 RISK ANALYSIS 105

6.2 COMPANY EVALUATION MATRIX: METHODOLOGY 105

6.3 AUTHOR DETAILS 108

Clinical Trial Supplies - Company Evaluation Report, 2025

Market Report | 2025-08-01 | 108 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$2650.00
	Corporate License	\$4250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-17"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com